Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study.
Tarlatamab produces longer-lasting responses in small-cell lung cancer than chemotherapy, with more patients achieving complete remission.
Secondary endpoints included investigator-assessed PFS, objective response, disease control, duration of response per RECIST v1;1, PROs, and safety. Objective response rate was 35;4% with tarlatamab, including six confirmed complete responses versus 20;4% with chemotherapy; at data cutoff, ongoing responses were observed in 31;1% (28/90) versus 3;8% (2/52) of responders, respectively.
What the study was
- Study design
- Randomized controlled trial
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- Ann Oncol
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.